Fig. 9: The KRAS/RAC1/ROS/NLRP3 axis is active in human leukemia cells.
From: Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
a The histogram shows mean fluorescence intensity (MFI) for H2DCF-DA in CD11b+ cells of AML patients with a KRAS mutation (Krasmut) or without a KRAS mutation (non-Krasmut). b The graph displays MFI fold change of H2DCF-DA expression in Krasmut (n = 11) and non-Krasmut (n = 10) AML patient cells, normalized to non-Krasmut in both stimulation conditions. c The histogram shows MFI for MitoSOX in Krasmut or non-Krasmut AML patients cells. d The graph displays MFI fold change of MitoSOX expression in Krasmut (n = 16) and non-Krasmut (n = 11) patient cells, normalized to non-Krasmut in both stimulation conditions. e The graph displays MFI fold change of IL-1β expression in Krasmut JMML patients cells, treated with DMSO (n = 5), Ebselen (n = 5) or PDTC (n = 5), normalized to DMSO-treated Krasmut. f Western blot shows the amount of caspase-1 (p20 subunit) in PBMCs isolated from Krasmut JMML patients treated with DMSO, Ebselen or PDTC after stimulation with 200 ng/ml LPS and 5 mM ATP. g The ratio of caspase-1 (p20 subunit)/β-actin in Krasmut PBMCs derived from JMML patients, treated with DMSO (n = 3), Ebselen (n = 3) or PDTC (n = 3), normalized to DMSO-treated Krasmut cells. h The histogram shows MFI for H2DCF-DA in Krasmut or non-Krasmut CMML patients cells. i The graph displays MFI fold change of H2DCF-DA expression in Krasmut (n = 5) and non-Krasmut (n = 13) CMML patients cells, normalized to non-Krasmut in both stimulation conditions. j The graph displays MFI fold change of IL-1β expression in Krasmut CMML patients cells, treated with DMSO (n = 5), Ebselen (n = 5) or PDTC (n = 5), normalized to DMSO-treated Krasmut cells. k The graph displays MFI fold change of IL-1β expression in Krasmut CMML patients cells, treated with DMSO (n = 5) or 100 µM of RAC1 inhibitor NSC 23766 (n = 5), after stimulation with 200 ng/ml LPS and 5 mM ATP, normalized to DMSO-treated Krasmut. l The graph displays MFI fold change of H2DCF-DA expression in Krasmut CMML patients cells, treated with DMSO (n = 5) or 100 µM of RAC1 inhibitor NSC 23766 (n = 5), after stimulation with 200 ng/ml LPS and 5 mM ATP, normalized to DMSO-treated Krasmut. All data are shown as mean ± SEM.
